Thyroid Dysfunction and Its Significance in Heart Failure.

INTRODUCTION:Studies show a high prevalence of thyroid dysfunction in heart failure patients that could have an impact on clinical course and outcome.MATERIALS:A total of 185 consecutive heart failure patients aged >18 years (mean age 58.4 years; 57.3% males) underwent demographic, clinical, hematological, biochemical and thyroid profile assessment. Euthyroidism was defined as TSH of 0.5 to 4.94 mIU/L with fT3 and fT4 in normal range, hypothyroidism as TSH of >4.94, and hyperthyroidism as TSH <0.5 mIU/L. Patients were followed up till discharge/outcome. Data was analyzed using SPSS 21.0 software.RESULT:Prevalence of thyroid disorders was 28.6% (6.5% hyper and 22.2% hypothyroid). No significant association of thyroid disorders was seen with age, sex, comorbidities and NT-proBNP levels (p > 0.05). Thyroid disorder was significantly associated with higher SBP, patients with NYHA 3/4, TSH, S. urea, S. creatinine and HDL levels and lower Hb, SGPT, TC and LDL levels (p < 0.05). Mean duration of hospital stay of patients with thyroid disorder was 3.74±0.92 days as compared to 3.45±0.86 days for those without thyroid disorder (p = 0.050). There were 12 (6.5%) mortalities. No significant association of mortality was seen with thyroid disorder (p = 0.711).CONCLUSION:There is high prevalence of thyroid disorders in heart failure patients which had a clinical impact too. Patients with thyroid disorder had higher NYHA and required longer hospitalization. Further studies to explore these relationships further are recommended. References Biondi B, Kahaly GJ. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat Rev Endocrinol 2010;6(8):431-443. Kuchulakanti PK, Bandaru S, Kuchulakanti A, et al. Association of subclinical hypothyroidism in heart failure: a study from South India. Br J Cardiol 2019;26:35. Jabbar A, Ingoe L, Thomas H, et al. Prevalence, predictors and outcomes of thyroid dysfunction in patients with acute myocardial infarction: the ThyrAMI-1 study. J Endocrinol Invest 2021;44(6):1209-1218.